Medical Assistant

TempraMed posts record July sales, then announces a CenterWell Pharmacy deal. The contract is dated August 25. TempraMed announced it on September 23, in a release whose news section runs a single sentence. The company on the other side of that sentence is CenterWell Pharmacy, the pharmacy services brand of Humana. CenterWell Pharmacy agreement dated August 25, announced September 23. TempraMed Technologies Ltd. (CSE: VIVI) (OTCQB: TMPTF) (FSE: 9DY) announced on September 23 that it has entered into a distribution agreement with CenterWell Pharmacy, Inc., which the company describes as the pharmacy services brand of Humana Inc. (NYSE: HUM), a major US health insurer. The agreement itself is dated August 25, 2026, four weeks before the announcement. The release does not explain the gap. The products involved are named only in the release's forward-looking statements, which refer to the anticipated distribution of VIVI Cap and VIVI Epi by CenterWell. TempraMed sells them as part of a line of patented thermal-insulation devices for temperature-sensitive medications, built to operate continuously without batteries or external power. The company calls these devices FDA-registered. In plain terms, registration means a manufacturer and its devices are listed with the agency; it is not FDA clearance or approval, and the release does not claim either. No dollar value was attached to the deal. No launch date either. CenterWell agreement carries no stated minimum orders and a 60-day exit. What terms were disclosed sit in the cautionary language rather than the announcement. Either party can terminate the agreement on 60 days' prior written notice, according to the release, and the same section warns there is no assurance that any orders will be placed or any revenue generated under it. One line there reads oddly. The phrase stating that the agreement "does not contain minimum purchase commitments" appears inside square brackets in the release as distributed on Newsfile, the kind of formatting a drafter uses to mark text for review. Taken at face value, it says CenterWell has not committed to buy anything. The release does not address whether the brackets were meant to come out before publication. Channel access is what TempraMed has here. Revenue from that channel is a separate matter the release leaves open. TempraMed reports record July sales of about US$522,000. Five days before the CenterWell news, TempraMed published an interim sales update. July 2026 sales reached approximately US$522,000, the highest monthly figure in the company's history. August came in at approximately US$403,000, its second-highest month. For the eight months ended August 31, sales totaled approximately US$2.07 million, already above the roughly US$1.8 million the company recorded for all of fiscal 2025. All of those figures are preliminary and unaudited. The company states they could change materially once its financial statements for the period ended September 30 are completed. August was also about 23% below July, which the release's "strong August performance" headline does not dwell on. Chief Executive Officer Ron Nagar attributed the growth to a push beyond direct-to-consumer sales into institutional, pharmacy, distributor and healthcare-system channels. Broader use of temperature-sensitive injectables, with insulin and GLP-1 medications named specifically, was cited by the company as a second driver. Those are management's explanations, not independently verified findings. Management also expects third-quarter 2026 sales to be significantly stronger than the same quarter of 2025; that is a forecast, not a reported result. Neither release disclosed a cash balance or a burn rate. No specific cash runway or going-concern language was identified in the sources reviewed for this article. TempraMed's Q3 2026 financial statements are expected in November. TempraMed has said its third-quarter 2026 financial statements are not expected until November. Those statements will be the first formal financial report covering the July and August sales the company has already previewed as estimates. No start date for distribution through CenterWell has been disclosed, and the company has not said it will report sales through that channel separately. Sources. Editorial disclosure. This article is based entirely on publicly available information, specifically TempraMed Technologies' September 23 and September 18, 2026 press releases as distributed by Newsfile. The securities discussed are TempraMed Technologies Ltd. (CSE: VIVI) (OTCQB: TMPTF) (FSE: 9DY) and Humana Inc. (NYSE: HUM), the latter referenced only as the parent of the counterparty, CenterWell Pharmacy, Inc. aktiego.com has not received any compensation from TempraMed, Humana, their management, investor relations representatives, or any third party. No staff member or principal of aktiego.com holds a position in either security at the time of publication. The CenterWell distribution agreement is dated August 25, 2026 and was announced September 23, 2026. Per the company's own cautionary language, there is no assurance that any orders will be placed or any revenue generated under it, and either party may terminate it on 60 days' written notice. The statement that the agreement contains no minimum purchase commitments appears in square brackets in the release as distributed; this article reports it as written. No dollar value, volume, or distribution start date was disclosed. This is a distribution arrangement, not contracted revenue. TempraMed's July, August, and year-to-date sales figures are preliminary, unaudited estimates that the company says may change materially on completion of its financial statements for the period ended September 30, 2026. Management's expectation of stronger third-quarter 2026 sales is a forward-looking statement. The company's reasons for its sales growth are its own characterizations and have not been independently verified by aktiego.com. TempraMed describes its devices as FDA-registered; registration is a listing step and does not constitute FDA clearance or approval. No specific cash runway, cash balance, or going-concern disclosure was identified in the sources reviewed. The Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of TempraMed's releases, per the company's own standard disclosure. Small cap and micro-cap stocks listed on the CSE, TSX, TSXV, and Nasdaq are speculative investments carrying significant risk including potential total loss of capital. Coverage on aktiego.com is provided for informational and educational purposes only. aktiego.com is not a registered investment advisor. Nothing in this article constitutes financial, investment, or professional advice. Readers are encouraged to conduct their own due diligence and consult a qualified financial advisor before making any investment decisions. For more information please see its full DISCLAIMER. More market insights on youtube. Watch its latest market briefings, CEO interviews and stock deep dives covering the companies and sectors AktieGo follow. Market Briefings 3x per week Stock Deep Dives In-depth analysis CEO Interviews Exclusive insights Emerging Sectors Mining · Tech · Energy · Biotech The AktieGo Brief The market moves fast. Its briefing keeps up. Curated updates on stock picks, company spotlights, and in-depth market analysis across mining, biotech, energy, crypto, and tech - delivered straight to your inbox. Join thousands of investors who start their morning with the AktieGo Brief. By submitting your information, you're giving AktieGo permission to email you. No spam, no excessive emails. You may unsubscribe at any time.

Addus COO departs; CenterWell names New president of home solutions. Heather Dixon leaves Addus, Brad Bickham steps in as interim chief operating officer. Heather Dixon, chief operating officer of home care services provider Addus HomeCare Corporation (Nasdaq: ADUS), has left the company after serving as president and COO since September 2025. "[Dixon] has been an important member of the team, and we are grateful for her partnership," Dirk Allison, CEO of Addus, said in a statement. "We also appreciate her commitment to our mission, which will continue in her absence. We wish her the best in her next chapter." Before joining Addus, Dixon served as chief financial officer of behavioral health provider Acadia Healthcare and as COO and then chief financial officer at primary care provider Everside Health. Former president and COO Brad Bickham has agreed to step back in as COO on an interim basis for one year, effective Aug. 10, according to an Addus release. Bickham played key roles in growing Addus' personal care platform, expanding the company's home health service arm and helming key acquisition strategies, Allison said. Frisco, Texas-based Addus HomeCare provides in-home care, home health and hospice throughout 264 locations across 24 states. CenterWell names Casey McKeon president of home solutions. CenterWell, a healthcare services business under the American health insurance giant Humana, named Casey McKeon president of home solutions. McKeon will lead Humana's home care strategy, operations and growth for CenterWell Home Health, OneHome and the company's home care model, a company spokesperson told Home Health Care News in an email. Previously, McKeon served as general manager of government business strategy and operations at health insurance firm Cigna, president and general manager of the value-based care platform CareAllies and held two director roles at Humana, according to his LinkedIn. CenterWell provides primary care, home health and pharmacy services for older adults across 350 locations and 37 states. HarmonyCares appoints new COO and chief financial officer. HarmonyCares named Tom Xu as COO and Manu Kuppalli as CFO as the company ramps up its next growth phase. Xu previously served as chief administrative officer for Oak Street Health, a primary care network acquired by retail drugstore chain CVS in a $10.6 billion deal in 2023. Kuppalli most recently served as CFO of virtual opioid use treatment company Bicycle Health. "We are excited to bring in leaders with deep expertise to lead the organization through our next chapter," HarmonyCares CEO Matt Chance said in a statement. "Tom's proven ability to scale operations and drive performance and Manu's track record in financial strategy and operational leadership will strengthen our ability to expand access while building the infrastructure needed to support our teams and long-term growth." Troy, Michigan-based HarmonyCares provides in-home primary care services across 12 states. The company rebranded from the name U.S. Medical Management in 2022. Denis Fleming Jr to serve as chief government affairs officer of National Alliance for Care at Home. The National Alliance for Care at Home (the Alliance) has tapped Denis Fleming Jr. as its chief government affairs officer. Fleming has previously served as the senior vice president and legislative counsel for state and federal affairs at Optum Home and Community Care Delivery/LHC Group and held a similar role at home care provider Almost Family, Inc. Fleming will help shape policies affecting home-based care, which will include directing legislative and regulatory teams and collaborating with policymakers, industry stakeholders and grassroots networks, according to the Alliance. "[Fleming's] deep policy expertise, extensive experience in advocacy, close relationships on Capitol Hill, and dedication to strengthening Americans' access to care at home will be invaluable to the future of the Alliance and advancing the policy interests of our members," Alliance CEO Jennifer Sheets said in a statement. The Alliance is an advocacy group focused on home care, hospice and palliative care. It formed in 2024 through a merger of the National Association for Home Care & Hospice and National Hospice and Palliative Care Organization. Rachel Vaughn to serve as Always Best Care's chief marketing officer. Always Best Care Senior Services appointed Rachel Vaughn as chief marketing officer. Vaughn will spearhead Always Best Care's marketing, branding strategies, customer experience and marketing technology experience while working closely with the company's 115 franchisees, according to the company. Vaughn previously served as CMO for salon suite rental company Salon Lofts. She held senior marketing leadership roles at companies including salon suite platform Sola Salons, franchising company WellBiz Brands, haircare services provider Floyd's 99 Barbershop and restaurant franchise Smashburger, according to her LinkedIn. "As we continue to grow, we wanted a marketing leader who understands franchising, knows how to build brands at scale and shares our commitment to helping franchisees succeed," Always Best Care President and CEO Jake Brown said in a statement. "Rachel brings that experience along with a genuine passion for our mission, and we're excited to welcome her to the leadership team." Rocklin, California-based Always Best Care provides in-home care, home health and other specialized care for older adults throughout 150 locations across the United States and Canada. Maxim Healthcare promotes Matthew Diaz to COO. Maxim Healthcare promoted Matthew Diaz from vice president of behavioral health to COO. As COO, Diaz will guide strategy and growth for Maxim's home care and behavioral operations service lines, bolster the company's expansion of Maxim behavioral services into home-based and clinical settings and advance technology initiatives, according to the company. "Over the past two decades, he has demonstrated an ongoing commitment to our mission, never losing sight of quality patient care," Maxim Healthcare CEO Jarrod DePriest said in a statement. "I am incredibly proud of the way he has led our teams and confident his vision and leadership will help guide Maxim into our next chapter." Diaz held various roles at Maxim from 2002 to 2016, before moving to AccentCare where he served as regional vice president, according to his LinkedIn profile. He then rejoined Maxim in 2017, according to his profile. Columbia, Maryland-based Maxim Healthcare provides home health, personal caregiving services, support for military and federal families and behavioral therapy services across 42 states. Kevin Rogers retires as VNA Health Group COO and CFO. Visiting Nurse Association (VNA) Health Group COO and CFO Officer Kevin Rogers will retire on Dec. 31, 2026. Rogers first joined the VNA Health Group in 2005 as vice president and CFO, a role he held until 2012, according to his LinkedIn profile. He went on to serve as the senior vice president and chief administrative officer at Visiting Nurse Service of New York and CEO at Care Finders Total Care before rejoining VNA Health Group in 2018. "Kevin has been one of the most trusted and respected leaders in our organization for many years," Christopher Rinn, president and CEO of VNA Health Group, said in a statement. "His leadership, strategic insight and commitment to our mission have positioned VNA Health Group for long-term success." VNA Health Group, based in Neptune, New Jersey, provides home health care, private-pay personal care services, children and family health services, hospice services and visiting physician services. The company was founded in 1912 and primarily serves New Jersey. Companies featured in this article: MK Manoylov is a Senior Reporter at Home Health Care News. Their work has appeared in publications including WebMD, Business Insider and LiveScience, in addition to governmental reports from the U.S. Department of the Treasury. MK earned a master's degree in journalism in the Science, Health and Environmental Reporting (SHERP) from New York University.